Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

被引:290
作者
Gallagher, Arlene M. [1 ]
Setakis, Efrosini [1 ]
Plumb, Jonathan M. [3 ]
Clemens, Andreas [3 ]
van Staa, Tjeerd-Pieter [1 ,2 ]
机构
[1] Med & Healthcare Prod Regulatory Agcy, London SW1W 95Z, England
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[3] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany
基金
英国医学研究理事会;
关键词
Atrial fibrillation; anticoagulation; stroke; treatment; warfarin; PREDICTING STROKE; GENERAL-PRACTICE; STRATIFICATION SCHEMES; ORAL ANTICOAGULANT; WARFARIN; THROMBOEMBOLISM; VALIDATION; MANAGEMENT; INTENSITY; THERAPY;
D O I
10.1160/TH11-05-0353
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA(2)DS(2)-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with <= 30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke.
引用
收藏
页码:968 / 977
页数:10
相关论文
共 28 条
[1]  
[Anonymous], PHARMACOVIGILANCE
[2]   Adequacy of anticoagulation in patients with atrial fibrillation: Effect of various parameters [J].
Cohen, N ;
Almoznino-Sarafian, D ;
Alon, I ;
Gorelik, O ;
Koopfer, M ;
Chachashvily, S ;
Shteinshnaider, M ;
Litvinjuk, V ;
Modai, D .
CLINICAL CARDIOLOGY, 2001, 24 (05) :380-384
[3]   Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].
Connolly, Stuart J. ;
Pogue, Janice ;
Eikelboom, John ;
Flaker, Gregory ;
Commerford, Patrick ;
Franzosi, Maria Grazia ;
Healey, Jeffrey S. ;
Yusuf, Salim .
CIRCULATION, 2008, 118 (20) :2029-2037
[4]   Newly Identified Events in the RE-LY Trial [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Reilly, Paul A. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1875-1876
[5]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[6]   Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin [J].
Currie, CJ ;
Jones, M ;
Goodfellow, J ;
McEwan, P ;
Morgan, CL ;
Emmas, C ;
Peters, JR .
HEART, 2006, 92 (02) :196-200
[7]   Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study [J].
Fang, Margaret C. ;
Go, Alan S. ;
Hylek, Elaine M. ;
Chang, Yuchiao ;
Henault, Lori E. ;
Jensvold, Nancy G. ;
Singer, Daniel E. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (08) :1231-1236
[8]   ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society [J].
Fuster, Valentin ;
Ryden, Lars E. ;
Cannom, David S. ;
Crijns, Harry J. ;
Curtis, Anne B. ;
Ellenbogen, Kenneth A. ;
Halperin, Jonathan L. ;
Le Heuzey, Jean-Yves ;
Kay, G. Neal ;
Lowe, James E. ;
Olsson, S. Bertil ;
Prystowsky, Eric N. ;
Tamargo, Juan Luis ;
Wann, Samuel .
CIRCULATION, 2006, 114 (07) :E257-E354
[9]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[10]   Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? [J].
Gallagher, A. M. ;
Rietbrock, S. ;
Plumb, J. ;
van Staa, T. P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1500-1506